Project Twenty21
PLEA are proud to support Drug Science’s observational study, Project Twenty21.
A registry aiming to enrol 20,000 patients, Project Twenty21 is creating the largest body of evidence in Europe for the safety and efficacy of cannabis-based medicinal products (CBMPs).
Supporting patient access, PLEA are excited to be collaborating with Drug Science and other Project Twenty21 partners to represent our patient community.
Drug Science and PLEA hope that the findings of Project Twenty21 will provide evidence for NHS funding where the benefits of treatment with medicinal cannabis is proven to outweigh the potential risks.
Offering patients subsidised access to CBMPs, the pilot will support prescribing clinicians across the country to feel confident in providing medical cannabis to their patients.
As a non-profit organisation, PLEA will only invest in projects that address accelerating access to prescribed CBMPs. We shall advocate for the patient community whilst remaining impartial and are not incentivised, influenced or motivated by financial gain. Our resources are offered to patients free of charge.